Search

Your search keyword '"Basir, Mir Babar"' showing total 8 results
Start Over Author "Basir, Mir Babar" Publisher elsevier
8 results on '"Basir, Mir Babar"'

1. List of contributors

Author

Abbott, J. Dawn, primary, Abi Rafeh, Nidal, additional, Abu Fadel, Mazen, additional, Agostoni, Pierfrancesco, additional, Akyuz, Sukru, additional, Alaswad, Khaldoon, additional, Alexopoulos, Dimitrios, additional, Angiolillo, Dominick J., additional, Aronow, Herbert D., additional, Avran, Alexandre, additional, Azzalini, Lorenzo, additional, Babunashvili, Avtandil M., additional, Bagai, Jayant, additional, Banerjee, Subhash, additional, Baran, Kenneth, additional, Basir, Mir Babar, additional, Boudou, Nicolas, additional, Boudoulas, Konstantinos Dean, additional, Bourantas, Christos V., additional, Božinović, Nenad Ž., additional, Bryniarski, Leszek, additional, Bufe, Alexander, additional, Burke, M. Nicholas, additional, Büttner, Heinz Joachim, additional, Cardoso, Pedro Pinto, additional, Carlino, Mauro, additional, Chambers, Jeff, additional, Charitakis, Konstantinos, additional, Chatzizisis, Yiannis S., additional, J. Chavez, Ivan, additional, Choi, James W., additional, Christiansen, Evald Høj, additional, Cohen, Mauricio G., additional, Costa, Francesco, additional, Damas de los Santos, Felix, additional, Dautov, Rustem, additional, De Martini, Tony, additional, Denktas, Ali E., additional, Dens, Joseph, additional, Dimitriadis, Zisis, additional, Doing, Anthony, additional, Egred, Mohaned, additional, Elbarouni, Basem, additional, El Guindy, Ahmed M., additional, El Sabbagh, Abdallah, additional, Fasseas, Panayotis, additional, Feldman, Dmitriy N., additional, Furkalo, Sergey, additional, Gagnor, Andrea, additional, Galassi, Alfredo R., additional, Garbo, Roberto, additional, Garcia, Santiago, additional, Gasparini, Gabriele L., additional, Gershlick, Anthony H., additional, Goessl, Mario, additional, Grancini, Luca, additional, Hakeem, Abdul, additional, Hall, Allison B., additional, Harb, Stefan, additional, Hatem, Raja, additional, Henriques, Jose P.S., additional, Jang, Yangsoo, additional, Jussila, Risto, additional, Kalnins, Artis, additional, Kalyanasundaram, Arun, additional, Kao, Paul Hsien-Li, additional, Karacsonyi, Judit, additional, Karagounis, Lampros, additional, Karanasos, Antonios, additional, Karmpaliotis, Dimitri, additional, Khalili, Houman, additional, Khatri, Jaikirshan J., additional, Khelimskii, Dmitrii, additional, Kim, Byeong-Keuk, additional, Kohl, Louis P., additional, Kolansky, Daniel M., additional, Koutouzis, Michalis, additional, Krestyaninov, Oleg, additional, Latif, Faisal, additional, Lee, Seung-Whan, additional, Lefevre, Thierry, additional, Lembo, Nicholas J., additional, Mahmud, Ehtisham, additional, Marmagkiolis, Konstantinos, additional, Mashayekhi, Kambis, additional, Mavromatis, Kreton, additional, Megaly, Michael, additional, Mogabgab, Owen, additional, Mooney, Michael R., additional, Moses, Jeffrey W., additional, Murad, Bilal, additional, Nap, Alexander, additional, Nicholson, William, additional, Nikas, Dimitrios N., additional, Nikolakopoulos, Ilias, additional, Olivecrona, Goran, additional, Omer, Mohamed A., additional, Oreglia, Jacopo Andrea, additional, Padilla, Lucio, additional, Paizis, Ioannis, additional, Panetta, Carmelo, additional, Patel, Mitul, additional, Pershad, Ashish, additional, Postu, Marin, additional, Potluri, Srini, additional, Poulose, Anil, additional, Pyxaras, Stylianos, additional, Rao, Sunil V., additional, Rathore, Sudhir, additional, Ravandi, Amir, additional, Reifart, Nicolaus, additional, Riley, Robert F., additional, Rinfret, Stephane, additional, Sandhu, Gurpreet S., additional, Sandoval, Yader, additional, Sanidas, Elias, additional, Santiago Trinidad, Ricardo, additional, Schussler, Jeffrey M., additional, Seto, Arnold, additional, Sharma, Alok, additional, Shaukat, Arslan, additional, Shishehbor, Mehdi H., additional, Shlofmitz, Evan, additional, Shlofmitz, Richard, additional, Sorajja, Paul, additional, Spaedy, Anthony, additional, Tajti, Peter, additional, Tamis-Holland, Jacqueline E., additional, Toma, Aurel, additional, Toutouzas, Konstantinos, additional, Traverse, Jay H., additional, Truong, Huu Tam, additional, Tsalamandris, Sotiris, additional, Tsiafoutis, Ioannis, additional, Ungi, Imre, additional, Vavouranakis, Emmanouil, additional, Vemmou, Evangelia, additional, Vo, Minh N., additional, Voudris, Vassilis, additional, Wang, Yale, additional, Wójcik, Jarosław, additional, Wollmuth, Jason, additional, Wu, Eugene B., additional, Xenogiannis, Iosif, additional, Yamane, Masahisa, additional, and Ybarra, Luiz Fernando, additional

Published
2021
Full Text
View/download PDF

2. Editorial: Defining the problem, the first step to making progress in acute myocardial infarction and cardiogenic shock care.

Author

Basir MB, Gorgis S, and Aurora L

Subjects
Humans, Treatment Outcome, Shock, Cardiogenic therapy, Shock, Cardiogenic diagnosis, Shock, Cardiogenic physiopathology, Shock, Cardiogenic mortality, Myocardial Infarction therapy, Myocardial Infarction diagnosis
Abstract

Competing Interests: Declaration of competing interest Basir: Abiomed, Boston Scientific, Chiesi, Saranas, Zoll.

Published
2024
Full Text
View/download PDF

3. Intravascular lithotripsy compared with rotational atherectomy for calcified coronary lesions: A meta-analysis of outcomes.

Author

Gupta R, Hosseinpour A, Patel C, Malik AH, Goel A, Bandyopadhyay D, Basir MB, Lavie CJ, Patel NC, and Bhatt DL

Subjects
Humans, Treatment Outcome, Risk Factors, Male, Aged, Female, Atherectomy, Coronary adverse effects, Lithotripsy, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Coronary Artery Disease therapy, Coronary Artery Disease diagnostic imaging
Abstract

Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Bhatt discloses the following relationships - Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures, Hims; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), CSL Behring (AHA lecture), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co‑leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Otsuka, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald's Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda.

Published
2024
Full Text
View/download PDF

5. Impact of calcium on the procedural techniques and outcomes of chronic total occlusion percutaneous coronary intervention.

Author

Kostantinis S, Rempakos A, Simsek B, Karacsonyi J, Allana SS, Alexandrou M, Gorgulu S, Alaswad K, Basir MB, Davies RE, Benton SM Jr, Krestyaninov O, Khelimskii D, Frizzell J, Ybarra LF, Bagur R, Reddy N, Kerrigan JL, Haddad EV, Love M, Elbarouni B, Soylu K, Yildirim U, Dattilo P, Azzalini L, Kearney K, Sadek Y, ElGuindy AM, Abi Rafeh N, Goktekin O, Mastrodemos OC, Rangan BV, Sandoval Y, Burke MN, and Brilakis ES

Subjects
Humans, Calcium, Risk Factors, Coronary Angiography methods, Chronic Disease, Treatment Outcome, Registries, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, Coronary Occlusion diagnosis, Coronary Occlusion surgery, Coronary Occlusion epidemiology, Calcinosis complications
Abstract

Background: Coronary calcification is common and increases the difficulty of chronic total occlusion (CTO) percutaneous coronary intervention (PCI)., Methods: We examined the impact of calcium on procedural outcomes of 13,079 CTO PCIs performed in 12,799 patients at 46 US and non-US centers between 2012 and 2023., Results: Moderate or severe calcification was present in 46.6% of CTO lesions. Patients whose lesions were calcified were older and more likely to have had prior coronary artery bypass graft surgery. Calcified lesions were more complex with higher J-CTO score (3.0 ± 1.1 vs. 1.9 ± 1.2; p < 0.001) and lower technical (83.0% vs. 89.9%; p < 0.001) and procedural (81.0% vs. 89.1%; p < 0.001) success rates compared with mildly calcified or non-calcified CTO lesions. The retrograde approach was more commonly used among cases with moderate/severe calcification (40.3% vs. 23.5%; p < 0.001). Balloon angioplasty (76.6%) was the most common lesion preparation technique for calcified lesions, followed by rotational atherectomy (7.3%), laser atherectomy (3.4%) and, intravascular lithotripsy (3.4%). The incidence of major adverse cardiovascular events (MACE) was higher in cases with moderate or severe calcification (3.0% vs. 1.2%; p < 0.001), as was the incidence of perforation (6.5% vs. 3.4%; p < 0.001). On multivariable analysis, the presence of moderate/severe calcification was independently associated with lower technical success (odds ratio, OR = 0.73, 95% CI: 0.63-0.84) and higher MACE (OR = 2.33, 95% CI: 1.66-3.27)., Conclusions: Moderate/severe calcification was present in nearly half of CTO lesions, and was associated with higher utilization of the retrograde approach, lower technical and procedural success rates, and higher incidence of in-hospital MACE., (Copyright © 2023 Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

6. Modified Transcaval Left Atrial Venoarterial Extracorporeal Membrane Oxygenation Without Preplanning Contrast CT: Step-by-Step Guide.

Author

Chiang M, Gonzalez PE, Basir MB, O'Neill BP, Lee J, Frisoli T, Wang DD, O'Neill WW, and Villablanca PA

Subjects
Hospital Mortality, Humans, Shock, Cardiogenic, Tomography, X-Ray Computed, Treatment Outcome, Extracorporeal Membrane Oxygenation
Abstract

Competing Interests: Funding Support and Author Disclosures Dr Basir is a consultant for Abbott Vascular, Abiomed, Cardiovascular Systems, Chiesi, Saranas, and Zoll. Dr B. O'Neill is a consultant to and receives research support from Edwards Lifesciences. Dr Frisoli is a proctor for Edwards Lifesciences, Abbott, Boston Scientific, and Medtronic. Dr Wang is a consultant to Edwards Lifesciences, Abbott, Neochord, and Boston Scientific; and receives institutional research grant support from Boston Scientific. Dr W. O'Neill has served as a consultant for Abiomed, Edwards Lifesciences, Medtronic, Boston Scientific, Abbott Vascular, and St. Jude Medical; and serves on the board of directors of Neovasc Inc. Dr Villablanca is a consultant for Edwards Lifesciences and Teleflex. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Published
2022
Full Text
View/download PDF

8. Beyond the Coronary Arteries, Should We Be Shifting Our Focus to Mechanical Circulatory Support in Patients With Acute Myocardial Infarction and Cardiogenic Shock?

Author

Basir MB

Subjects
Catheterization, Coronary Vessels, Humans, Laboratories, Myocardium, Shock, Cardiogenic diagnosis, Shock, Cardiogenic etiology, Shock, Cardiogenic therapy, Heart-Assist Devices, Myocardial Infarction therapy, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction surgery
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results